通过点击化学构建三醇修饰的奇纳林衍生物作为选择性的c-MYC G-四重复合联体和强大的抗癌剂
Jiong-Heng Cai1, Dan-Yan Yang1, Jun-Jie Zhang1
1School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou 510006, China.
Bioorganic chemistry
|February 9, 2024
概括
研究人员开发了新的三醇修饰的奇纳 (TMQ) 衍生物,可以稳定c-MYC G-quadruplex (G4) 结构. 化合物A6选择性地抑制c-MYC转录并抑制癌细胞的进展,提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- c-MYC瘤基因在瘤发生过程中至关重要,并且在癌症中经常过度表达.
- 在c-MYC促进体中的G-四重复 (G4) 结构可以抑制其表达.
- 用小分子准c-MYC G4是一种潜在的癌症治疗策略.
研究的目的:
- 开发新型的三醇修饰的quinazoline (TMQ) 衍生物作为c-MYC G-quadruplex的选择性配体.
- 评估这些衍生物抑制c-MYC转录和抑制癌细胞增殖的能力.
- 确定具有改进c-MYC G4稳定性和抗癌性能的化合物.
主要方法:
- 从4-anilinoquinazoline中合成TMQ衍生物,使用点击化学.
- 评估c-MYC G4在癌细胞系中的稳定潜力和抗增殖活性.
- 对c-MYC G4的化合物选择性的评估及其对c-MYC转录的影响.
主要成果:
- 一系列TMQ衍生物被合成和评估.
- 在c-MYC G4稳定能力和抗增殖活性之间观察到强烈的相关性,特别是在HCT116结肠直肠癌细胞中.
- 与化合物相比,化合物A6在c-MYC G4稳定和c-MYC转录抑制方面表现出更好的选择性.
- A6诱导了G4形成,选择性地抑制了与G4相关的c-MYC转录,并抑制了HCT116细胞进展.
结论:
- TMQ衍生物,特别是A6化合物,是有效的c-MYC G4稳定剂和转录抑制剂.
- 化合物A6显示出作为选择性c-MYC向治疗剂的承诺,用于由c-MYC驱动的癌症.
- 这些发现为设计针对癌症治疗的优化c-MYC G4向配体提供了宝贵的见解.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


